Drug profile · INN
entacapone
COMTAN
entacapone (COMTAN) is a catechol o-methyltransferase inhibitor. Associated with Sandoz Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — entacapone
- US status
- approved
- Class
- Nervous system (N04)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
entacapone (COMTAN) is a catechol o-methyltransferase inhibitor. Associated with Sandoz Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Catechol O-methyltransferase inhibitor
Primary target: Catechol O-methyltransferase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is entacapone?
entacapone (COMTAN) is a catechol o-methyltransferase inhibitor. Associated with Sandoz Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for entacapone?
COMTAN is a marketed brand name for entacapone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of entacapone?
entacapone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.